In the BioHarmony Drug Report Database

"Preview" Icon

Agomelatine

Thymanax, Valdoxan (agomelatine) is a small molecule pharmaceutical. Agomelatine was first approved as Thymanax on 2009-02-19. It has been approved in Europe to treat major depressive disorder. The pharmaceutical is active against melatonin receptor type 1A and melatonin receptor type 1B. In addition, it is known to target 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 2C.

 

Trade Name

 

Thymanax, Valdoxan
 

Common Name

 

agomelatine
 

ChEMBL ID

 

CHEMBL10878
 

Indication

 

major depressive disorder
 

Drug Class

 

Image (chem structure or protein)

Agomelatine structure rendering